RA839

RA839 is a selective Nrf2/ARE pathway agonist and non-covalent small molecule binder of Keap1 (Kd is approximately 6 μM) . RA839 prevents inducible nitric oxide synthase expression and nitric oxide release. RA839 exerts anti-rotaviral and anti-inflammatory effects[1][2].

Product Specifications

CAS Number

[1832713-02-6]

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Keap1-Nrf2; NO Synthase

Type

Reference compound

Related Pathways

Immunology/Inflammation; NF-κB

Applications

Cancer-programmed cell death

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/ra839.html

Purity

98.54

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C([C@@H]1CN(C2=C3C=CC=CC3=C(NS(=O)(C4=C(C)C(C)=CC(C)=C4C)=O)C=C2)CC1)O

Molecular Formula

C25H28N2O4S

Molecular Weight

452.57

Precautions

H302, H315, H319

References & Citations

[1]Winkel AF, et al. Characterization of RA839, a Noncovalent Small Molecule Binder to Keap1 and Selective Activator of Nrf2 Signaling. J Biol Chem. 2015;290 (47) :28446-28455.|[2]Patra U, et al. RA-839, a selective agonist of Nrf2/ARE pathway, exerts potent anti-rotaviral efficacy in vitro. Antiviral Res. 2019 Jan;161:53-62.